Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in systemic autoimmune rheumatic disease-associated interstitial lung disease
CTR20251234Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nerandomilast in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by Boehringer Ingelheim. Started Sep 2025; status: active.
02
Drugs
nerandomilast
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on CTR20251234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251234.